Hoofnagle et al. were the first to describe that interferon alpha, when given to patients with non-A, non-B hepatitis, was able to normalize liver enzyme levels in a substantial number of patients. They also noted that relapses might occur if treatment was discontinued1. This observation was confirmed by other smaller controlled and uncontrolled studies. Subsequently the genome of HCV was cloned and its nucleotide sequence determined which lead to development of tests for antibody to HCV (antiHCV) using recombinant antigen. Since then a number of studies have been performed in hepatitis C and it is generally accepted that interferon is the most effective therapy for it. In one of the largest studies published recently by Alberti et al. 12 a high initial response of 65-70% with 6 MU thrice weekly as compared to 56-58% response with 3 MU thrice weekly was reported. The present study was done to assess the short term effects of treatment with alpha-interferon on patients with chronic hepatitis C.